ITGAM and neoplasm: Combining the CD11b agonist ADH‐503 with anti‐PD‐1 immunotherapy and chemotherapy leads to a significant reduction in tumor cell viability, proliferation, metabolic activity, immunomodulation, and secretion of immunosuppressive and tumor growth‐promoting cytokines.